Download image

VM Rivastigmine

Visual representation of the interaction
Mode of action
Transporter zone
No interaction
Enzyme zone
Receptor zone
No interaction
Ion channel zone
No interaction

NbN-2 rivastigmine

Molecular structure
NbN_library O O N CH 3 H CH 3 H 3 C CH 3 CH 3 N
Mode of action
enzyme inhibitor (acetylcholinesterase, butyrylacetycholinesterase)
Pharmacological target
Date published


For more detailed explanation of the principles of the VM Library
For more detailed explanation of the Neuroscience based Nomenclature

Please notice that Caution should be applied when extrapolating animal data to humans.

Detailed and Approved Information on the clinical use of the compounds can be found at the homepage of EMA or at Martindale.

  1. Luo W, Yu QS, Kulkarni SS, et al. (2006) Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem 49: 2174-2185.
  2. Deardorff WJ, Feen E and Grossberg GT. (2015) The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease. Drugs Aging 32: 537-547.
  3. Ali TB, Schleret TR, Reilly BM, et al. (2015) Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada. PLoS One 10: e0144337.
  4. NbN-2
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country